Results 171 to 180 of about 17,879 (261)

Reduced SH3RF3 May Protect Against Alzheimer's Disease by Lowering Microglial Pro‐Inflammatory Responses via Modulation of JNK and NFkB Signaling

open access: yesGlia, Volume 74, Issue 7, July 2026.
SNPs in SH3RF3 decrease the age of onset of Alzheimer's disease (AD). Reduced SH3RF3 blunts human microglial JNK and NFkB signaling and downstream inflammatory cytokine production, which may partially explain how SH3RF3 SNPs protect against AD. ABSTRACT Understanding how high‐risk individuals are protected from Alzheimer's disease (AD) may illuminate ...
Ronak Patel   +13 more
wiley   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 198-209, 1 July 2026.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi   +29 more
wiley   +1 more source

Centromeric retrotransposons shape chromosomal evolution beyond pericentromeric regions. [PDF]

open access: yesMob DNA
Poretti M   +5 more
europepmc   +1 more source

Quantifying Protein–Glycan Interactions Using Native Mass Spectrometry

open access: yesMass Spectrometry Reviews, Volume 45, Issue 4, Page 800-828, July/August 2026.
ABSTRACT Interactions between glycan‐binding proteins (GBPs) and carbohydrates (glycans) are essential to many biological processes relevant to human health and disease. For most GBPs, however, their glycan interactome—the repertoire of glycans recognized and their specificities—is poorly defined.
Duong T. Bui   +4 more
wiley   +1 more source

A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials

open access: yesPharmaceutical Statistics, Volume 25, Issue 4, July/August 2026.
ABSTRACT Adaptive clinical dose‐finding trials aim to identify an optimal drug dose for use in subsequent phase II and III trials. In adaptive dose‐finding trials, dose levels for newly included patients are informed by outcomes of patients that received the drug earlier in the trial.
Rob Kessels   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy